PP159. In women with previous pregnancy hypertension, cardiovascular risk biomarkers may be modulated by haptoglobin genotype

Abstract

Preeclampsia may affect the risk for future cardiovascular disease. Haptoglobin (Hp), an acute phase protein with genetic polymorphism (Hp1.1, 2.1 and 2.2) synthesized in the hepatocyte and in many tissues, may modulate the risk through the antioxidant and anti-inflammatory differential effects of their genotypes. Evaluate some parameters of cardiovascular risk in association with genetic polymorphism of Hp in women with previous preeclampsia (HBP) compared to healthy women during gestation (NBP). We studied 352 women aged 35±5.48 current year, taking these, 165 presented previous preeclampsia, 2-14 (±6.6) years ago. Genetic polymorphism of Hp was determined from plasma by electrophoresis. The different circulating biomarkers, myeloperoxidase ng/mL (MPO) and nitrates and nitrites (nmol/ml) by ELISA, transaminases - AST and ALT (U/L) and apolipoprotein A and B (mg/dL), uric acid (mg/dl) hs-CRP (mg/L) were determined by conventional methods as well as blood pressure (BP) and anthropometric parameters BMI and hip and waist circumference (WC).Statistical methods were Chi-square, ANOVA (Bonferroni) and t-Student. There were no differences in the distribution of phenotypes of Hp between NBP and those with previous hypertension in pregnancy. There were differences between NBP and HBP in the following parameters: Systolic BP (118.9±13.4 vs 135.0±16.5, p<0.001); Diastolic BP (72.2±10.1 vs 85.9±12.0 p<0.001); MPO (62.3±30.9 vs 85.7±39.4, p=0.020); Nitrite (10.1±3.8 vs 19.1±7.0, p<0.001); ALT (18.0±8.0 vs 22.5±12.9, p=0.016); BMI (25.4±4.1 vs 27.1±4.8, p=0.031); WC (82.8±9.9 vs 89.5±15.6, p=0.002); Apo B (0.6±0.1 vs 0.6±0.1, p=0.023). Those values vary with the genotypes of Hp and were observed Hp 1.1 and 2.1 in NBP and HBP respectively: [Systolic BP 119.2±13.7 vs 134.7±18.3 (p<0.001); Diastolic BP (72.8±11.9 vs 86.2±19.4 p<0.001); MPO (57.9±32.5 vs 94.2±42.1, p=0.008); Nitrites (9.6±3.2 vs 20.0±8.5, p<0.001); ALT(17.0±7.2 vs 20.4±8.0, p=0.033); WC (82.4±10.0 vs 90.8±17.6, p=0.004); Apo A (0.9±0.2 vs 1.0±0.2, p=0.011)] and Hp 2.2 in NBP and HBP respectively: [Systolic BP 118.2±13.1 vs 135.6±12.8 (p<0.001); Diastolic BP (70.9±7.2 vs 85.5±16.3 p<0.001); Nitrites (11.5±5.1 vs 18.0±4.4, p<0.001)]. Women with previous hypertension during pregnancy, presented significant differences in some classic cardiovascular risk biomarkers as well as in some others, associated with the inflammatory process, whose variation may be modulated by haptoglobin functional genetic polymorphism. The history of hypertensive disease in pregnancy may be relevant, in association with these biomarkers to the prevention of cardiovascular disease in particular of postmenopausal women.